Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).
Angioedema
Inform patients and/or their caregivers that Toviaz may cause angioedema, which could result in life-threatening airway obstruction. Advise patients and/or their caregivers to promptly discontinue Toviaz and seek immediate medical attention if they experience edema of the lips, tongue or laryngopharynx, or difficulty breathing.
Antimuscarinic Effects
Inform patients that Toviaz, like other antimuscarinic agents, may produce clinically significant adverse effects related to antimuscarinic pharmacological activity including constipation and urinary retention. Toviaz, like other antimuscarinics, may be associated with blurred vision, therefore, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects on the patient have been determined. Heat prostration (due to decreased sweating) can occur when Toviaz, like other antimuscarinic drugs, is used in a hot environment.
Alcohol
Patients should also be informed that alcohol may enhance the drowsiness caused by Toviaz, like other anticholinergic agents.
This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).
Angioedema
Inform patients and/or their caregivers that Toviaz may cause angioedema, which could result in life-threatening airway obstruction. Advise patients and/or their caregivers to promptly discontinue Toviaz and seek immediate medical attention if they experience edema of the lips, tongue or laryngopharynx, or difficulty breathing.
Antimuscarinic Effects
Inform patients that Toviaz, like other antimuscarinic agents, may produce clinically significant adverse effects related to antimuscarinic pharmacological activity including constipation and urinary retention. Toviaz, like other antimuscarinics, may be associated with blurred vision, therefore, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects on the patient have been determined. Heat prostration (due to decreased sweating) can occur when Toviaz, like other antimuscarinic drugs, is used in a hot environment.
Alcohol
Patients should also be informed that alcohol may enhance the drowsiness caused by Toviaz, like other anticholinergic agents.
This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.